Disc Medicine, Inc. (IRON)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$74.51-0.69%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Disc Medicine, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	3.7M
EPS	—	-1.679
Annual ending 2026-12-31
Revenue	—	3.16M
EPS	—	-6.323
Annual ending 2027-12-31
Revenue	—	32.54M
EPS	—	-6.698

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain cash and capital near $730 million by end 2026	It plans $730 million in cash by end 2026.	Intact	cash falls significantly below $700 million by end 2026	Cash and cash equivalents: $98.676M FY2026-Q2; GAAP. Published target: ~$730 million cash. Target period ends 2026-12-31; this observation covers 2026-Q2. Source date unavailable98,676,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_balance_sheet. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Generate meaningful revenue growth starting in 2027	A primary condition in Disc Medicine, Inc.'s published investment case. The stated target is Revenue >= $32 million in 2027.	Intact	revenue fails to reach $20 million in 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Complete workforce restructuring aligned with strategic priorities	A primary condition in Disc Medicine, Inc.'s published investment case. The stated target is Restructuring plan implemented and workforce aligned.	Improving	restructuring plan stalls or reverses by end 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-6.70

$-7.59 → $-6.70 · observed estimates

FY2027 revenue$0.03B

$0.03B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-7.59	$32,236,480	9 / 12
2026-07-25	$-7.59	$32,236,480	9 / 12
2026-07-26	$-7.59	$32,236,480	9 / 12
2026-07-27	$-7.37	$32,229,858	9 / 9
2026-07-28	$-7.59	$32,236,480	9 / 12
2026-07-29	$-7.37	$32,229,858	9 / 9
2026-07-30	$-7.59	$32,236,480	9 / 12
2026-07-31	$-7.46	$32,236,480	9 / 12
2026-08-01	$-7.37	$32,229,858	9 / 9
2026-08-02	$-7.46	$32,236,480	9 / 12
2026-08-03	$-7.30	$29,383,790	9 / 11
2026-08-04	$-7.30	$29,383,790	9 / 11
2026-08-05	$-7.23	$33,685,140	9 / 12
2026-08-06	$-7.23	$33,685,140	9 / 12
2026-08-07	$-7.04	$33,686,892	9 / 8
2026-08-08	$-7.04	$33,686,892	9 / 8
2026-08-09	$-7.27	$33,685,140	9 / 12
2026-08-10	$-7.04	$33,686,892	9 / 8
2026-08-12	$-7.27	$33,685,140	9 / 12
2026-08-13	$-7.04	$33,686,892	9 / 8
2026-08-14	$-7.04	$33,686,892	9 / 8
2026-08-15	$-7.04	$33,686,892	9 / 8
2026-08-16	$-7.04	$33,686,892	9 / 8
2026-08-17	$-7.04	$33,686,892	9 / 8
2026-08-18	$-7.04	$33,686,892	9 / 8
2026-08-19	$-7.04	$33,686,892	9 / 8
2026-08-20	$-7.06	$33,853,339	9 / 9
2026-08-21	$-7.06	$33,853,339	9 / 9
2026-08-22	$-7.06	$33,853,339	9 / 9
2026-08-23	$-7.06	$33,853,339	9 / 9
2026-08-24	$-7.06	$33,853,339	9 / 9
2026-08-25	$-7.06	$33,853,339	9 / 9
2026-08-26	$-7.06	$33,853,339	9 / 9
2026-08-27	$-7.06	$33,853,339	9 / 9
2026-08-28	$-7.06	$33,853,339	9 / 9
2026-08-29	$-7.06	$33,853,339	9 / 9
2026-08-30	$-7.06	$33,853,339	9 / 9
2026-08-31	$-7.06	$33,853,339	9 / 9
2026-09-01	$-7.06	$33,853,339	9 / 9
2026-09-02	$-7.06	$33,853,339	9 / 9
2026-09-03	$-7.06	$33,853,339	9 / 9
2026-09-04	$-7.13	$33,853,372	9 / 9
2026-09-05	$-7.13	$33,853,372	9 / 9
2026-09-06	$-7.13	$33,853,372	9 / 9
2026-09-07	$-7.13	$33,853,372	9 / 9
2026-09-08	$-7.13	$33,853,372	9 / 9
2026-09-09	$-7.13	$33,853,372	9 / 9
2026-09-10	$-7.13	$33,853,372	9 / 9
2026-09-11	$-7.13	$33,853,339	9 / 9
2026-09-12	$-7.13	$33,853,339	9 / 9
2026-09-13	$-7.13	$33,853,339	9 / 9
2026-09-14	$-7.13	$33,853,339	9 / 9
2026-09-15	$-7.13	$33,853,339	9 / 9
2026-09-16	$-7.13	$33,853,339	9 / 9
2026-09-17	$-7.00	$34,853,339	9 / 9
2026-09-18	$-7.00	$34,853,339	9 / 9
2026-09-19	$-7.00	$34,853,339	9 / 9
2026-09-20	$-6.85	$34,853,339	9 / 9
2026-09-21	$-6.85	$34,853,339	9 / 9
2026-09-22	$-6.85	$34,853,339	9 / 9
2026-09-23	$-6.85	$34,853,339	9 / 9
2026-09-24	$-6.85	$34,853,339	9 / 9
2026-09-25	$-6.85	$34,853,339	9 / 9
2026-09-26	$-6.85	$34,853,339	9 / 9
2026-09-27	$-6.85	$34,853,339	9 / 9
2026-09-28	$-6.85	$34,853,339	9 / 9
2026-09-29	$-6.85	$34,853,339	9 / 9
2026-09-30	$-6.85	$34,853,339	9 / 9
2026-10-01	$-6.85	$34,853,339	9 / 9
2026-10-02	$-6.85	$34,853,339	9 / 9
2026-10-03	$-6.85	$34,853,339	9 / 9
2026-10-04	$-6.85	$34,853,339	9 / 9
2026-10-05	$-6.85	$34,853,339	9 / 9
2026-10-06	$-6.85	$34,853,339	9 / 9
2026-10-07	$-6.85	$34,853,339	9 / 9
2026-10-08	$-6.85	$34,853,339	9 / 9
2026-10-09	$-6.85	$34,853,339	9 / 9
2026-10-10	$-6.85	$34,853,339	9 / 9
2026-10-11	$-6.85	$34,853,339	9 / 9
2026-10-12	$-6.85	$34,853,339	9 / 9
2026-10-13	$-6.85	$34,853,339	9 / 9
2026-10-14	$-6.85	$34,853,339	9 / 9
2026-10-15	$-6.85	$34,853,339	9 / 9
2026-10-16	$-6.85	$34,853,339	9 / 9
2026-10-17	$-6.85	$34,853,339	9 / 9
2026-10-18	$-6.85	$34,853,339	9 / 9
2026-10-19	$-6.85	$34,853,339	9 / 9
2026-10-20	$-6.85	$34,853,339	9 / 9
2026-10-21	$-6.72	$32,313,186	9 / 9
2026-10-22	$-6.72	$32,313,186	8 / 9
2026-10-23	$-6.70	$32,538,186	8 / 8
2026-10-24	$-6.70	$32,538,186	8 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	13	0	0
2026-06-01	13	0	0
2026-07-01	13	0	0
2026-08-01	13	0	0
2026-09-01	13	0	0
2026-10-01	13	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades6 maintains

Recent actions · Sep 25–Oct 24 · 6 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

JefferiesOct 21 · prior Sep 10

$128.00 → $149.00+16.4%

Wells FargoOct 20 · prior Sep 16

$86.00 → $124.00+44.2%

Morgan StanleyOct 20 · prior Aug 17

$90.00 → $92.00+2.2%

Cantor FitzgeraldOct 20

$170.00New observation · no comparable prior

Truist FinancialOct 19

$115.00New observation · no comparable prior

BMO CapitalOct 19

$120.00New observation · no comparable prior

$0$93.50$187.00

3 raises · 0 cuts · 0 unchanged · 3 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain cash and capital near $730 million by end 2026Cash and cash equivalents: $98.676M
Generate meaningful revenue growth starting in 2027Direct metric needs a verified mapping
Complete workforce restructuring aligned with strategic prioritiesDirect metric needs a verified mapping

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-40.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Disc Medicine, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage healthcare company, not an established earnings compounder. The multi-year view is mixed: several programs have reached concrete milestones, while losses and elevated risk keep confidence low.

What's priced into Disc Medicine, Inc.

The evidence does not provide a valuation level or a clear account of market expectations, so whether IRON is cheap or expensive versus peers cannot be assessed. The recent thesis reaction has been muted, and no pricing fragility signals were triggered.

What the fundamentals likely do

Near term, the October earnings beat is positive, but recent financial performance remains below its industry cohort and the company is loss-making. APOLLO showed significant results on its co-primary endpoints, while management plans to resubmit the NDA by year-end 2026; regulatory completion is still pending. Cash was lower at the June quarter-end than at March, though management says the balance funds operations into 2029.

What Disc Medicine, Inc. hinges on

The multi-year thesis hinges on completing the planned bitopertin resubmission and advancing DISC-0974 and DISC-3405. A guidance cut or further weakening in jobs data would add near-term pressure, while continued strength among healthcare bellwethers could support the sector backdrop. The supplied evidence offers limited detail on the litigation and debt issuance announced on October 22.